Research programme: anticancer non-immunogenic monoclonal antibodies - Antitope/Fusion Antibodies
Latest Information Update: 11 Dec 2013
At a glance
- Originator Antitope; Fusion Antibodies
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 01 Aug 2013 Research activities are ongoing in Ireland
- 26 Jul 2013 Antitope has been acquired by PolyTherics